# A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV

> **NCT07635992** · PHASE1 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 18 (estimated)

## Conditions studied

- HIV (Human Immunodeficiency Virus)

## Interventions

- **DRUG:** Ibalizumab Combined with Chidamide

## Key facts

- **NCT ID:** NCT07635992
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07635992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07635992, "A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07635992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*